Citigroup analyst Andrew Baum maintains Eli Lilly and Co with a Buy

By / / Eli Lilly

Citigroup analyst Andrew Baum maintains Eli Lilly and Co with a Buy and raises the price target from $675 to $895.

Scroll to Top